Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Syndesi Therapeutics SA

www.syndesitherapeutics.com

Latest From Syndesi Therapeutics SA

UCB Spinout Syndesi Brings New Approach To Dementia

Emerging Company Profile: Syndesi Therapeutics, a new biotech built upon research from UCB, aims to develop novel drugs for neurodegenerative conditions like Alzheimer's disease; the company has a stream of big name investors such as J&J Innovation and Novo Holdings.

StartUps and SMEs Neurology

Venture Funding Deals: MedImmune Spinout Viela Lands $250m Series A

China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Syndesi Therapeutics SA
  • Senior Management
  • Jonathan Savidge, PhD, CEO
    John Kemp, PhD, CSO
    Charlotte Videbaek, MD, CMO
    Cesura Andrea , PhD, Head, Preclinical Dev.
  • Contact Info
  • Syndesi Therapeutics SA
    Phone: 10 280 238
    Chemin du Cyclotron 6
    CEI Incubator
    Louvain-la-Neuve, 1348
    Belgium
Advertisement
Advertisement
UsernamePublicRestriction

Register